In vitro study of peritoneal fibrosis

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  Hung, Kuan Yu ^a   Wu, Kuan Dun ^a   Tsai, Tun Jun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cytokine; Fibroblast; In vitro study; Mesothelial cell; Peritoneal fibrosis; Tamoxifen

Indexed keywords

CYTOKINE; GROWTH FACTOR; TAMOXIFEN;

ASIA; CONFERENCE PAPER; DATA ANALYSIS; FIBROBLAST; FIBROSIS; HUMAN; IN VITRO STUDY; PATHOGENESIS; PERITONEAL DISEASE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; FIBROSIS; HUMANS; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; PERITONEUM;

EID: 35748972973     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Mendelssohn DC. Peritoneal dialysis and the future: the role of peritoneal dialysis in the overall management of end-stage renal disease. Blood Purif 2003; 21:20-8.
2. Hung KY, Lin TJ, Tsai TJ, Chen WY. Impact of peritoneal membrane transport on technique failure and patient survival in a population on automated peritoneal dialysis. ASAIO J 1999; 45:568-73.
3. Davis SJ, Philips L, Griffiths AM, Russell RH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207-17.
4. Williams JD, Craig KJ, Topley N, Williams GT. Peritoneal dialysis: changes to the structure of the peritoneal membrane and potential for biocompatible solutions. Kidney Int 2003; 63(Suppl 84):S158-61.
5. Hung KY, Huang JW, Tsai TJ. Peritoneal fibrosing syndrome: pathogenetic mechanism and current therapeutic strategies. J Chin Med Assoc 2005; 68:401-5.
6. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
7. Chin AI, Yeun JY. Encapsulating peritoneal sclerosis: an unpredictable and devastating complication of peritoneal dialysis. Am J Kidney Dis 2006; 47:697-712.
8. Topley N. Encapsulating peritoneal sclerosis: time to act. Perit Dial Int 2006; 26:564-5.
9. Di Paoto N, Sacchi G. Atlas of peritoneal histotogy. Perit Dial Int 2000; 20(Suppl 3):S5-96.
10. Hung KY, Tsai TJ, Chen WY. Peritoneal fibrosis and its prevention. Nephrology 2002; 7:227-32.
11. Yung S, Li FK, Chan TM. Peritoneal mesothelial cell culture and biology. Perit Dial Int 2006; 26:162-73.
12. Witowski O, Jörres A. Peritoneal cell culture: fibroblasts. Perit Dial Int 2006; 26:292-9.
13. Kumano K, Ma P, Hyodo T, Sakai T. Effects of osmotic agents on hyaluronan synthesis in human peritoneal mesothelial cells and fibroblasts. Adv Perit Dial 1997; 13:58-63.
14. Yang WS, Kim BS, Lee SK, Park JS, Kim SB. Interleukin-1β stimulates the production of extracellular matrix in cultured human peritoneal mesothelial cells. Perit Dial Int 1999; 19:211-20.
15. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-β1 of human peritoneat mesothelial cells: effect of cytokine costimulation. Perit Dial Int 1999; 19:221-30.
16. Yang AH, Chen JY, Lin YP, Huang TP, Wu CW. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997; 51:1280-8.
17. Tsai TJ, Yen CJ, Fang CC, Yang CC, Lee PH, Yen TS. Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Nephron 1995; 71:23-8.
18. Fang CC, Yen CJ, Chen YM, Ko FN, Tsai TJ, Lee PH, et al. Hydralazine inhibits human peritoneal mesothelial cell proliferation and collagen synthesis. Nephrol Dial Transplant 1996: 11:2276-81.
19. Ha H, Cha MK, Choi HN, Lee HB. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22:171-7.
20. Lai KN, Leung JC, Chan LY, Li FF, Tang SC, Lam MF, et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol 2004; 138:466-75.
21. Do JY, Kim YL, Park JW, Cho KH, Kim TW, Yoon KW, et al. The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3):S22-5.
22. Aguitera A, Yanez-Mo M, Selgas R, Sanchez-Madrid F, Lopez-Cabrera M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs 2005; 6:262-8.
23. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan 3A, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
24. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothetial cells. Kidney Int 2003; 63:1530-9.
25. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-β1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
26. Rodrigues A, Martins M, Santos MJ, Fonseca I, Otiveira JC, Cabrita A, et al. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interteukin-6: relationship with peritoneal transport. Adv Perit Dial 2004; 20:8-12.
27. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-β1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59:463-70.
28. Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int 2004; 65:1170-9.
29. Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits PDGF-stimulated human peritoneal mesothetial cell proliferation. Kidney Int 2001; 60:872-81.
30. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS. Dipyridamole inhibits TGF-β-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001; 60:1249-57.
31. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ. Pentoxifylline modulates intracellular signaling of TGF-β in cultured human peritoneal mesothetial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003; 18:670-6.
32. Xu ZG, Kim KS, Park HC, Choi KH, Lee HY, Han DS, et al. High glucose activates the p38 MAPK pathwayin cultured human peritoneal mesothelial cells. Kidney Int 2003; 63: 958-68.
33. Szeto CC, Lai KB, Chow KM, Szeto CY, Wong TY, Li PK. Differential effects of transforming growth factor-β on the synthesis of connective tissue growth factor and vascular endothetiat growth factor by peritoneal mesothelial cell. Nephron Exp Nephrol 2005; 99:e95-104.
34. Szeto CC, Chow KM, Lai KB, Szeto CY, Kwan BC, Li PK. Connective tissue growth factor is responsible for transforming growth factor-β-induced peritoneal mesothelial cell apoptosis. Nephron Exp Nephrol 2006; 103:e166-74.
35. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-β1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25:38-47.
36. Ogata S, Yorioka N, Kohno N. glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. J Am Soc Nephrol 2001; 12:2787-96.
37. Yung S, Liu ZH, Lai KN, Li LS, Chan TM. Emodin ameliorates glucose-induced morphologic abnormalities and synthesis of transforming growth factor β1 and fibronectin by human peritoneal mesothetial cells. Perit Dial Int 2001; 21(Suppl 3):S41-7.
38. Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS, Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003; 64: 519-33.
39. Kakuta T, Tanaka R, Satoh Y, Izuhara Y, Inagi R, Nangaku M, et al. Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats. Kidney Int 2005; 68:1326-36.
40. Allaria PM, Giangrande A, Gandini E, Pisoni IB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent? J Nephrol 1999; 12:395-7.
41. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32-5.
42. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68:2381-8.
43. Ettoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203-6.